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Abstract
Background: In non-gastrointestinal stromal tumor soft tissue sarcoma (non-GIST STS) optimal treatment is surgery with
wide resection margins. Vascular endothelial growth factors (VEGFs) and receptors (VEGFRs) are known to be key players in
the initiation of angiogenesis and lymphangiogenesis. This study investigates the prognostic impact of VEGFs and VEGFRs
in non-GIST STS with wide and non-wide resection margins.
Methods: Tumor samples from 249 patients with non-GIST STS were obtained and tissue microarrays were constructed for
each specimen. Immunohistochemistry was used to evaluate the expressions of VEGF-A, -C and -D and VEGFR-1, -2 and -3.
Results: In the univariate analyses, VEGF-A (P = 0.040) in the total material, and VEGF-A (P = 0.018), VEGF-C (P = 0.025) and
VEGFR-3 (P = 0.027) in the subgroup with wide resection margins, were significant negative prognostic indicators of disease-
specific survival (DSS). In the multivariate analysis, high expression of VEGFR-3 (P = 0.042, HR = 1.907, 95% CI 1.024-3.549)
was an independent significant negative prognostic marker for DSS among patients with wide resection margins.
Conclusion: VEGFR-3 is a strong and independent negative prognostic marker for non-GIST STSs with wide resection
margins.
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Introduction
Soft tissue sarcomas (STS) originate from the mesenchymal
lineage, and thus share a similar ancestry [1]. Despite the fact that
the STS group of tumors cover over 50 different histological
entities, the occurrence of these tumors amounts to only 0.5% of
the annual cancer incidence [1,2]. The STSs are among the most
aggressive cancer types [2] with a lethality of 40–50%. About
10.000 new cases and 4.000 related deaths were registered in the
US in 2009 [2].
Classically STSs have been treated as a single group. This is
mainly because the low incidence makes it difficult to conduct
decently powered studies on the individual histological entities.
With the emerging knowledge of cellular processes and the
increasing knowledge about common and uncommon genetic
translocations the last decade, it is now clear that the picture might
be more intricate. For instance, Ewing family tumors, synovial
sarcoma, rhabdomyosarcoma, dermatofibrosarcoma protuberens
and others have distinct genetic translocations [3,4,5]. However,
the genetic translocations specific for the histological entities have
few implications for treatment options. Therefore it is still
adequate to group the remaining STSs together under the
proposed name of non-gastrointestinal stromal tumor STS (non-
GIST STS), although this might change in the future [4].
The main treatment of sarcomas is surgical resection, and wide
resection margins are considered one of the most important
prognostic factors [6]. However, a considerable variability in
prognosis has been observed for subsets of patients with wide
resection margins. Consequently, the clinical incorporation of
predictive and prognostic molecular biomarkers together with
traditional clinical prognostic factors will be pivotal for future
management of patients within this large subgroup.
Angiogenesis inhibitors provide a new and exciting therapeutic
option for patients with STS [7]. However, the angiogenesis
pathway in STS needs to be further examined to improve the
treatment strategy [7].The vascular endothelial growth factors
(VEGFs) and their receptors (VEGFRs) are well known targets in
antiangiogenic treatment. The VEGF super-family consist of six
ligands, placental growth factor (PlG), VEGF-A, -B, -C, -D and -E,
and three receptors, VEGFR-1, -2 and -3. VEGFR-1 binds PlG
and VEGF-A and -B, VEGFR-2 binds VEGF-A, -C and -D and
VEGFR-3 binds VEGF-C and -D [8]. VEGF-A signaling through
VEGFR-2 is considered the major angiogenic pathway, leading
endothelial cells (ECs) to proliferate, sprout and form tubes.
PLoS ONE | www.plosone.org 1 December 2010 | Volume 5 | Issue 12 | e15368
VEGFR-1 signaling has been implicated in regulating VEGFR-2
mediated angiogenesis [9]. VEGF-C and VEGF-D have been
shown to induce lymphangiogenesis through VEGFR-3 [8,10].
The latter has also been implicated in controlling angiogenic
sprouting [11].
High levels of VEGF-A in tumors and blood samples from STS
patients have previously been associated with higher tumor grade,
increased tendency to metastasis, reduced response to treatment,
lower overall survival (OS) and increased risk of recurrence
[12,13,14,15,16,17]. In angiosarcomas, however, high expression
of VEGFR-2 has been associated with longer OS [18]. VEGF-C
and VEGFR-3 overexpression has also been reported in STSs
[19].
In this study, the aim was to assess the prognostic impact of
VEGF-A, -C, -D and VEGFR-1. -2 and -3 in non-GIST STS
patients with wide and non-wide resection margins.
Methods
Patients and Clinical Samples
Primary tumor tissue from anonymized patients diagnosed with
non-GIST STS at the University Hospital of North-Norway and
the Hospitals of Arkhangelsk county, Russia, from 1973 through
2006, were collected. In total 496 patients were registered from the
hospital databases. Of these 247, patients were excluded from the
study due to: missing clinical data (n = 86) or inadequate paraffin-
embedded fixed tissue blocks (n = 161). Thus 249 patients with
complete medical records and adequate paraffin-embedded tissue
blocks were eligible.
This report includes follow-up data as of September 2009. The
median follow-up was 37.6 (range 0.1–391.7) months. Complete
demographic and clinical data were collected retrospectively.
Formalin-fixed and paraffin-embedded tumor specimens were
obtained from the archives of the Departments of Pathology at the
University Hospital of North-Norway and the Hospitals of
Arkhangelsk County. The tumors were graded according to the
French Fédération Nationale des centres de Lutte Contre le
Cancer (FNCLCC) system and histologically sub typed according
to the World Health Organization guidelines [1,20]. Wide
resection margins were defined as wide local resection with free
microscopic margins or amputation of the affected limb or organ.
Non-wide resection margins were defined as marginal or
intralesional resection margins, or no surgery.
Microarray construction
All sarcomas were histologically reviewed by two trained
pathologists (S. Sorbye and A. Valkov) and the most representative
areas of tumor cells (neoplastic mesenchymal cells) were carefully
selected and marked on the hematoxylin and eosin (H/E) slide and
sampled for the tissue microarray (TMA) blocks. The TMAs were
assembled using a tissue-arraying instrument (Beecher Instru-
ments, Silver Springs, MD). The Detailed methodology has been
previously reported [21]. Briefly, we used a 0.6 mm diameter
stylet, and the study specimens were routinely sampled with four
replicate core samples from different areas of neoplastic tissue.
Normal tissue from the patients was used as staining control.
To include all core samples, 12 TMA blocks were constructed.
Multiple 5-mm sections were cut with a Micron microtome
(HM355S) and stained by specific antibodies for immunohisto-
chemistry (IHC) analysis.
Immunohistochemistry
The applied antibodies were subjected to in-house validation by
the manufacturer for immunohistochemical analysis on paraffin-
embedded material. The antibodies used in the study were as follows:
VEGF-A (1:10, rabbit polyclonal; RB-1678; Neomarkers), VEGF-C
(1:25, rabbit polyclonal; 18-2255; Zymed Laboratories), VEGF-D
(1:40, mouse monoclonal; MAB286; R&D Systems), VEGFR-1
(1:10, rabbit polyclonal; RB-1527; Neomarkers), VEGFR-2 (1:25,
rabbit polyclonal; RB-9239; Neomarkers), and VEGFR-3 (1:10,
rabbit polyclonal; Sc-321; Santa Cruz Biotechnology).
Sections were deparaffinized with xylene and rehydrated with
ethanol. Antigen retrieval was done by placing the specimen in
0.01 mol/L of citrate buffer at pH 6.0 and exposed to repeated
(twice) microwave heating of 10 min (except VEGFR-3, twice for
5 min) at 450 W. VEGF-D was heated for 45 min in a water bath
in 0.01 mol/L of citrate buffer. The DAKO EnVision+ System-
HRP kit (diaminobenzidine) was used for endogen peroxidase
blocking. As negative staining controls, the primary antibodies
were replaced with the primary antibody diluents. Primary
antibodies were incubated for 30 min in room temperature
(except VEGFR-3, 20 min, and VEGF-D, overnight at 4uC).
The DAKO EnVision+ System-HRP kit (diaminobenzidine) was
used to visualize the antigens. This was followed by the application
of liquid diaminobenzidine and substrate-chromogen, yielding a
brown reaction product at the site of the target antigen. Finally, all
slides were counterstained with hematoxylin to visualize the nuclei.
For each antibody, included negative staining controls, all TMA
staining were done in a single experiment.
Scoring of immunohistochemistry
The ARIOL imaging system (Genetix, San Jose, CA) was used
to scan the slides of antibody staining of the TMAs. The slides
were loaded in the automated slide loader (Applied Imaging SL
50) and the specimens were scanned at low resolution (1.256) and
high resolution (206) using the Olympus BX 61 microscope with
an automated platform (Prior). Representative and viable tissue
sections were scored manually on computer screen semi
quantitatively for cytoplasmic staining. The dominant staining
intensity was scored as: 0 = negative; 1 = weak; 2 = intermediate;
3 = strong. All samples were anonymized and independently
scored by two trained pathologists (A. Valkov and S. Sorbye).
When assessing a variable for a given core, the observers were
blinded to the scores of the other variables and to outcome. Mean
score for duplicate cores from each individual was calculated
separately.
High expression in tumor cells was defined as score $1.5
(VEGF-A, VEGF-D, VEGFR-1-3) and $1 (VEGF-C) (Fig. 1).
Statistical Methods
All statistical analyses were done using the statistical package
SPSS (Chicago, IL), version 16. The IHC scores from each
observer were compared for interobserver reliability by use of a
two-way random effect model with absolute agreement definition.
The intraclass correlation coefficient (reliability coefficient) was
obtained from these results. The Chi-square test and Fishers Exact
test were used to examine the association between molecular
marker expression and various clinicopathological parameters.
Univariate analyses were done using the Kaplan-Meier method,
and statistical significance between survival curves was assessed by
the log rank test. DSS was determined from the date of diagnosis
to the time of cancer related death. To assess the independent
value of different pretreatment variables on survival, in the
presence of other variables, multivariate analyses were carried out
using the Cox proportional hazards model. Only variables of
significant value from the univariate analyses were entered into the
Cox regression analyses. Probability for stepwise entry and
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removal was set at .05 and .10, respectively. The significance level
used for all statistical tests was P,0.05.
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The clinopathological variables are summarized in Table 1.
The median age was 59 (range 0–91) years, 56% were female, 167
patients were Norwegian and 82 Russian. The Non-GIST STSs
comprised 249 tumors including angiosarcoma (n = 13), fibrosar-
coma (n = 20), leiomyosarcoma (n = 64), liposarcoma (n = 34),
undifferentiated pleomorphic sarcoma (n = 58), neurofibrosarco-
ma/malignant peripheral nerve sheath tumor (MPNST, n = 11),
rhabdomyosarcoma (n = 16), synovial sarcoma (n = 16) and
unspecified sarcoma (n = 17). The tumor origins were distributed
as follows: 36% extremities, 19% trunk, 15% retroperitoneal, 7%
head/neck and 23% visceral. Of 228 patients who underwent
surgery, 53% received surgery alone, 24% surgery and radiother-
apy, 18% surgery and chemotherapy and 6% surgery, radiother-
apy and chemotherapy. Besides, 21 patients did not undergo
surgery due to inoperable tumor (n = 11), high age/other serious
disease (n = 5), STS confirmed at autopsy (n = 3) and patient
refusal (n = 2). Of these unresected patients, seven patients
received chemotherapy and/or radiotherapy, whereas 14 patients
received no anticancer therapy.
Interobserver variability
Interobserver scoring agreement was tested for one ligand
(VEGF-C) and one receptor (VEGFR-3). The intraclass correla-
tion coefficients were 0.810 for VEGF-C (P,0.001) and 0.834 for
VEGFR-3 (P,0.001) indicating good reproducibility between the
two investigating pathologists.
Expression of VEGFs/VEGFRs and their Correlations
VEGF/VEGFR expression was observed in the cytoplasm of
tumor cells. For the ligand and receptor expressions we found the
following correlation with malignancy grade: High VEGF-A
expression, grade 1: 29%, grade 2: 48%, grade 3: 56% (P = 0.005);
High VEGF-C expression, grade 1: 24%, grade 2: 41%, grade 3:
45% (P = 0.032); High VEGFR-1 expression, grade 1: 27%, grade
2: 36%, grade 3: 48% (P = 0.034); High VEGFR-2 expression,
grade 1: 12%, grade 2: 27%, grade 3: 39% (P = 0.001).
Univariate Analyses
Table 1 summarizes the prognostic impact of the clinicopath-
ological variables in the total material. In the univariate analyses,
Figure 1. IHC analysis of TMA of non-GIST STSs representing different scores for tumor cell VEGF-C and VEGFR-3. (A) Tumor cell
VEGF-C high score in leiomyosarcoma; (B) Tumor cell VEGF-C low score in leiomyosarcoma; (C) Tumor cell VEGFR-3 high score in undifferentiated
pleomorphic sarcoma; (D) Tumor cell VEGFR-3 low score in liposarcoma. Abbreviations: IHC, immunohistochemistry; non-GIST STS, non-
gastrointestinal stromal tumor soft-tissue sarcoma TMA, tissue microarray; VEGF, vascular endothelial growth factor; VEGFR, vascular endothelial
growth factor receptor.
doi:10.1371/journal.pone.0015368.g001
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Table 1. Prognostic relevance of clinicopathological variables for disease-specific survival in 249 non-gastrointestinal stromal
tumor soft-tissue sarcomas (univariate analyses, log rank test).
Characteristics Patients (n) Patients (%)
Median survival
(months) 5-Year survival (%) P
Age
# 20 years 20 8 15 40 0.126
21–60 years 113 45 68 52
.60 years 116 47 30 40
Gender
Male 110 44 41 46 0.390
Female 139 56 45 45
Patient nationality
Norwegian 167 67 63 51 0.011




58 23 54 47 0.001
Leiomyosarcoma 64 26 48 48
Liposarcoma 34 14 NR 67
Fibrosarcoma 20 8 44 50
Angiosarcoma 13 5 10 31
Rhabdomyosarcoma 16 6 17 38
MPNST 11 4 49 45
Synovial sarcoma 16 6 31 29
Sarcoma NOS 17 7 9 18
Tumor localization
Extremities 89 36 100 53 0.348
Trunk 47 29 32 44
Retroperitoneum 37 25 25 38
Head/Neck 18 7 15 41
Visceral 58 23 30 42
Tumor size
#5 cm 74 30 127 57 0.027
5–10 cm 91 37 44 45
.10 cm 81 32 28 37
Missing 3 1
Malignancy grade
1 61 25 NR 74 ,0.001
2 98 39 41 45
3 90 36 16 26
Tumor depth
Superficial 17 7 NR 93 ,0.001
Deep 232 93 36 42
Metastasis at diagnosis
No 206 83 76 53 ,0.001
Yes 43 17 10 10
Surgery
Yes 228 92 59 50 ,0.001
No 21 8 5 0
Resection margins
Wide 108 43 NR 62 ,0.001
Non-wide/no surgery 141 57 21 33
Vascular Endothelial Growth Factors in Sarcoma
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patient nationality (P = 0.011), histological entity (P = 0.001),
tumor size (P = 0.027), malignancy grade (P,0.001), tumor depth
(P,0.001), metastasis at diagnosis (P,0.001), surgery (P,0.001)
and surgical margins (P,0.001) were all significant prognostic
indicators for DSS. In the subgroup with wide resection margins
(n = 108), patient nationality (P,0.001), malignancy grade
(P,0.001), tumor depth (P = 0.009) and metastasis at diagnosis
(P,0.001) were prognostic indicators of DSS. In the subgroup
with non-wide resection margins (n = 141), malignancy grade
(P,0.001), surgery (P,0.001), metastasis at time of diagnosis
(P,0.001) and histological entity (P = 0.005) were prognostic
indicators of DSS.
Characteristics Patients (n) Patients (%)
Median survival
(months) 5-Year survival (%) P
Chemotherapy
No 191 77 52 47 0.424
Yes 58 23 29 40
Radiotherapy
No 176 71 48 46 0.590
Yes 73 29 38 43
Abbreviations: NR, not reached; MPNST, malignant peripheral nerve sheath tumor; NOS, not otherwise specified.
doi:10.1371/journal.pone.0015368.t001
Table 1. Cont.
Table 2. Tumor expression of VEGFs and VEGFRs and their prognostic relevance for disease-specific survival in patients with non-
gastrointestinal soft-tissue sarcomas in the total material (univariate analyses; log-rank test, N = 249) and in subgroups with wide
and non-wide resection margins (univariate analyses; log-rank test, N = 108 and 141 respectively).


































Low 127 51 59 50 0.040 57 53 NR 69 0.018 70 50 21 34 0.508
High 109 44 31 42 48 44 63 52 61 43 21 34
Missing 13 5 3 3 10 7
VEGF C
Low 142 57 59 49 0.239 62 57 NR 70 0.025 80 57 18 33 0.989
High 88 35 38 45 43 40 68 52 45 32 28 37
Missing 19 8 3 3 16 11
VEGF D
Low 157 63 57 48 0.276 64 59 NR 64 0.267 93 66 23 37 0.169
High 83 33 36 42 43 40 120 57 40 28 11 25
Missing 9 4 1 1 8 6
VEGFR 1
Low 145 58 57 48 0.262 66 61 NR 64 0.110 79 56 23 34 0.963
High 89 36 41 46 40 37 120 58 49 35 21 36
Missing 15 6 2 2 13 9
VEGFR 2
Low 164 66 57 48 0.246 80 74 NR 65 0.135 84 60 18 31 0.689
High 63 25 31 44 24 22 68 52 39 28 26 38
Missing 22 9 4 4 18 13
VEGFR 3
Low 148 59 54 48 0.275 66 61 NR 67 0.027 82 58 21 32 0.753
High 81 33 41 44 38 35 63 51 43 31 23 37
Missing 20 8 34 4 16 11
Abbreviations: NR, not reached.
doi:10.1371/journal.pone.0015368.t002
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The influence on DSS by the VEGFs and VEGFRs are given in
Table 2 and Figure 2 (VEGF-C and VEGFR-3). In the total
material, VEGF-A expression (P = 0.040) was a significant
negative prognostic indicator of DSS. In the subgroup with wide
resection margins, VEGF-A (P = 0.018), VEGF-C (P = 0.025) and
VEGFR-3 (P = 0.027) expressions were significant negative
prognostic indicators of DSS. In the subgroup with non-wide
resection margins, neither the VEGFs nor VEGFRs were
indicators of DSS.
Multivariate Cox Proportional Hazards Analysis
Results of the multivariate analyses are presented in Tables 3 and
4. In the total material, tumor depth (P = 0.046), tumor size
(P = 0.045), high malignancy grade (P,0.001), lack of surgery
(P,0.001), non-wide resection margins (P = 0.004) and metastasis
at diagnosis (P,0.001), but none of the angiogenic markers, were
significant independent prognostic indicators of DSS (Table 3). In the
wide resection margins group, Russian nationality (P = 0.013), high
malignancy grade (P = 0.009), metastasis at diagnosis (P = 0.007) and
high VEGFR-3 expression (P = 0.042, HR = 1.907, 95% CI 1.024-
3.549) were significant independent prognostic indicators for reduced
DSS (Table 4). In the group with non-wide resection margins, high
malignancy grade (P,0.001), lack of surgery (P,0.001) and
metastasis at time of diagnosis (P,0.001) were independent
prognostic indicators of poor DSS.
Discussion
In this study we observed that high expression of VEGFR-3 was
a significant independent negative prognostic indicator of DSS in
non-GIST STS patients with wide resection margins. Although
there have been prior evaluations of the VEGF axis in STSs, these
have primarily been focused on VEGF-A. Herein, we have
presented a large-scale study of the prognostic impact of VEGF-A,
-C and -D and VEGFR-1-3 in non-GIST STS patients. To our
knowledge, this is the first evaluation of these pathways according
to resection margins.
The major weakness of this study, normally seen in sarcoma
studies in general, is the heterogeneity of the sarcoma population.
Even with a relatively large sample cohort with regard to non-
GIST STSs, the numbers are too small to do meaningful
explorations according to histological subgroups, at least with
respect to multivariate analysis.
Wide resection margins have been demonstrated to give the best
overall survival, with more modest results for marginal and
particularly intralesional resections [6]. Despite wide resection
margins 40% of patients in our population succumbed to their
sarcoma within five years. Identification of prognostic markers
within this group of patients is therefore of great interest.
This is the first report of VEGFR-3 expression being an
independent negative prognostic marker in non-GIST with wide
resection margins. VEGFR-3 is a tyrosine-kinase receptor that is
activated by VEGF-C and -D. The VEGFR-3/VEGF-C/-D
system is considered the main pathway responsible for developing
lymphatic vessels [8]. During the organogenesis, VEGFR-3 is
expressed in all endothelia, but as the organism matures the
expression has been associated mainly with lymphangiogenesis
[22]. In a small series of 32 STSs, Friedrichs et al. found that
around 50% of the tumors contained confirmable lymphatic
vessels and expressed VEGFR-3 and VEGF-C [19]. In contrast,
recent data have shown that VEGFR-3 is expressed in the
lamellopodia of lead-cells in angiogenic sprouts, indicating that
VEGFR-3 may play an important role also in angiogenesis [11].
This has been further supported by the fact that co-administration
Figure 2. Disease-specific survival curves for VEGF-C and VEGFR-3 in the total material and in the group with wide and non-wide
resection margins. (A) VEGF-C, total material; (B) VEGF-C, wide resection margins; (C) VEGF-C, non-wide resection margins; (D) VEGFR-3, total
material; (E) VEGFR-3, wide resection margins; (F) VEGFR-3, non-wide resection margins. Abbreviations: VEGF, vascular endothelial growth factor;
VEGFR, vascular endothelial growth factor receptor.
doi:10.1371/journal.pone.0015368.g002
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of VEGFR-2 and VEGFR-3 antibodies lead to a more extensive
suppression of angiogenesis than VEGFR-2 antibodies alone [11].
Through Folkman’s work on angiogenesis we know that without
blood-supply a tumor cannot grow beyond 1–2 mm3 in size [23].
This means that the angiogenic capabilities of VEGFR-3 may be
driving tumor angiogenesis and ultimately tumor development in
non-GIST STS patients. As the vascular and not the lymphatic
system is the principal metastatic pathway in non-GIST STSs, it is
natural to assume that increased angiogenesis will augment the risk
for metastasis development [24]. Increased vascularity will also
lead to increased interstitial fluid pressure (IFP), which inhibits
drug delivery to the tumor [25]. Since VEGFR-3 is a strong
lymphangiogenic factor, one could assume a worse DSS mediated
by high expression levels of VEGFR-3 was due to increased
lymphangiogenesis and subsequent lymph node metastasis,
although this is rare for sarcomas [24,26]. VEGFR-3 may also
function as a transducer of survival signals through autocrine
pathways with tumor-derived VEGF-C or -D or autoactivation of
the receptor itself [8].
In the presented population with wide resection margins, tumor
VEGF-C expression was a significant negative prognostic marker
for DSS. To our knowledge, only one small study has previously
reported on this relationship in STSs. In 45 patients with
undifferentiated pleomorphic sarcoma (previously malignant
fibrous histiocytoma, MFH) and neurogenic sarcoma, Hoffmann
et al. concluded surprisingly that high expression of VEGF-C
mRNA led to a longer overall survival [27]. This is inconsistent
with our findings and may be explained by sampling variation or
lacking translation of mRNA to protein in the tumors. VEGF-C
can interact with both VEGFR-2 and VEGFR-3, leading to
migration of ECs and increased capillary permeability [8,9]. These
effects are thought to be mediated through VEGFR-2 in vascular
ECs and through VEGFR-3 in lymphatic ECs [8,9]. In tumors
this will lead to angiogenesis, lymphangiogenesis and increased
IFP, which promote tumor sustenance, progression, metastasis and
resistance to cytotoxic therapy.
We found VEGF-A expression in tumor tissue to be a significant
negative prognostic marker for DSS in univariate analyses, both in
the total material and in the subgroup with wide resection
margins. Further, we found that VEGF-A and its corresponding
receptors VEGFR-1 and -2, showed significant correlations with
histological tumor grade, in accordance with previously published
studies [12,13,17]. VEGF-A activation of its corresponding
receptors, VEGFR-1 and -2, is known to be the major angiogenic
pathway [8]. The close correlation between these markers and
histological grade suggests that they play a role in the development
of many of the non-GIST STSs, either through angiogenesis or
other stroma-associated mechanisms.
Antibodies targeting the VEGF/VEGFR systems are readily
available, and clinical trials with such agents have been initiated in
several cancer types [28]. However, proper criteria for selecting
patients to treatment with these drugs are still lacking [28]. For the
employment of antiangiogenic drugs, side effects have to be
carefully weighed against efficacy, especially for patients with
intermediate to good prognosis. Hence, enhanced knowledge
about these molecules and their impact on different types of cancer
is pivotal.
As our data are prognostic and not mechanistic we cannot
conclude on which pathways are operative in non-GIST STSs
expressing VEGFs and VEGFRs. Nevertheless, it can be deduced
that VEGFs and VEGFRs play critical roles in sarcoma
progression and prognosis. But whether angiogenic ligands and
receptors may have predictive effects with respect to therapy
remains unanswered. The mechanistic impacts of angiogenesis,
lymphangiogenesis, autocrine versus paracrine pathways as well as
the relevance of constitutively activated receptors have to be
further clarified. Consequently, future translational research in this
field is needed.
Table 3. Results of the Cox regression analysis of the total
material.
Factor Hazard Ratio 95% CI P
Tumor depth
Superficial 1.000
Deep 7.541 1.040–54.661 0.046
Tumor size 0.045*
#5 cm 1.000
5–10 cm 1.420 0.895–2.252 0.136
.10 cm 1.858 1.140–3.030 0.013
Malignancy grade ,0.001*
1 1.000
2 2.892 1.660–5.040 ,0.001
3 4.192 2.421–7.259 ,0.001
Surgery
Yes 1.000
No 8.426 4.311–16.469 ,0.001
Resection margins
Wide 1.000
Non-wide 1.785 1.209–2.637 0.004
Metastasis at time of diagnosis
No 1.000
Yes 2.551 1.672–3.893 ,0.001
*Overall significance as a prognostic factor.
doi:10.1371/journal.pone.0015368.t003
Table 4. Results of the Cox regression analysis among
patients with wide resection margins.
Factor Hazard Ratio 95% CI P
Patient nationality
Norwegian 1.000
Russian 2.257 1.186–4.295 0.013
Malignancy grade 0.009*
1 1.000
2 3.672 1.200–11.240 0.023
3 5.484 1.828–16.447 0.002
Metastasis at time of diagnosis
No 1.000
Yes 2.900 1.332–6.315 0.007
VEGFR-3
Low 1.000
High 1.907 1.024–3.549 0.042
*Overall significance as a prognostic factor.
doi:10.1371/journal.pone.0015368.t004
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